Best of ASCO - 2014 Annual Meeting

 

Welcome

Advanced Disease

Genitourinary (Prostate) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
BRCA2-RB1 co-loss and ADT resistance in aggressive prostate cancer.

Goutam Chakraborty

e17024

A phase 2 trial of darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with AR targeting agents and non-progressive on a subsequent taxane (SAKK 08/16).

Richard Cathomas

TPS5087

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19).

Rahul Raj Aggarwal

TPS5090

A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).

Megan Crumbaker

TPS5088

A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC).

Earle Frederick Burgess

TPS5094

A population-based analysis of the effectiveness of docetaxel for castration-sensitive prostate cancer (CSPC).

Jean-Michel Lavoie

e17026

A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).

Michael J. Morris

TPS5092

A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).

Cora N. Sternberg

5008

A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen

5000

A retrospective, feasibility study of biweekly docetaxel in patients with high-risk, metastatic, hormone-sensitive, or castration-naive prostate cancer (mHSPC or mCNPC).

Sung Won Lim

e17000

A transcriptome analysis of castration resistant prostate cancer metastases in a prospective cohort study reveals high expression of AKT pathway genes predictive of long term response to abiraterone acetate/prednisone.

Manish Kohli

5038

Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).

Daniel J. George

LBA5009

Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.

Wolfgang Fendler

5001

Age-dependent administration and survival benefit of androgen deprivation therapy (ADT) vs. chemotherapy plus ADT (C+ADT) in metastatic prostate cancer (mPC).

Matthew Keating

e17046

Association between health-related quality of life (HRQoL) and clinical outcomes in non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.

Gerhardt Attard

5043

Association of clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis: Results of the CATS database.

Stephane Oudard

e17007

Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.

Andrew W Hahn

5048

Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC).

Matthew Raymond Smith

5032

Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases.

Li Zhang

5049

c15-148: Phase I/II trial of concurrent chemohormonal therapy using enzalutamide and cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC).

Julie Nicole Graff

TPS5097

c15-149: A phase 1b study of the oral CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer (mCRPC)—A prostate cancer clinical trials consortium study.

Catriona Lewis

e17028

c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study.

Dana E. Rathkopf

5045

Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): Real-life use, effectiveness, safety, and quality of life (QoL) in the FUJI cohort.

Stephane Oudard

5025

Can tumor contact length predict extracapsular extension, lymph node involvement, and biochemical recurrence?

Públio Viana

e17016

Cancer-related morbidity at the end of life in men with prostate cancer.

Divya Yerramilli

5042

Cardiovascular and metabolic toxicity of abiraterone in castration-resistant prostate cancer: Post-marketing experience.

Phoebe A. Cheng

e17043

Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.

Celestia S. Higano

e17018

Clinical outcomes following androgen receptor axis therapies (ARAT) among men with prostate cancer (PCa) having major cardiovascular diseases (CVDs) or extreme polypharmacy (EPP): A population based study.

Grace L. Lu-Yao

5056

Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer.

Anis Hamid

5055

Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples.

Howard I. Scher

5054

Combination of niclosamide to target androgen receptor variant 7 (AR-V7) and abiraterone to target androgen synthesis for the treatment of castration-resistant prostate cancer (CRPC): Initial results from a phase Ib/II trial.

Chong-xian Pan

5031

Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer (mHSPC): An updated network meta-analysis and cost minimization analysis in China.

Xin Hu

e17008

Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

Minke Smits

5036

Correlation of obesity and metabolic syndrome with higher tumor percentage involvement in high and intermediate prostate cancer patients.

Arash Samiei

e17048

CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.

Gang Chen

TPS5096

Current treatment trajectory for castration-resistant prostate cancer in the community setting.

Kjel Andrew Johnson

e17050

Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.

Xiao X. Wei

e17041

Dendritic cell (DC) based cryoimmunotherapy (CryoIT) in a prospective phase I trial of metastatic castration resistant prostate cancer (mCRPC): Interim analysis.

Alfred Honoré

e17014

DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.

Rahul Raj Aggarwal

5039

Docetaxel in hormone-sensitive prostate cancer with low Gleason scores: A meta-analysis of randomized controlled trials.

Omer Dizdar

e17032

Effect of PSA and Gleason score on survival of metastatic prostate cancer.

Samip R. Master

e17042

Effect of VERU-111, a novel oral inhibitor of α and β tubulin, on tumor growth in the human castration-resistant prostate cancer model 22Rv1.

Mark Christopher Markowski

e17003

Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men ≥ 80 years: A retrospective cohort study.

Daniel Khalaf

5051

Efficacy of abiraterone or enzalutamide following docetaxel chemotherapy in the hormone-sensitive setting.

Nick Waldron

e17022

Efficacy of radium-223 in bone-metastatic prostate cancer patients with and without homologous repair deficiency (HRD) mutations.

Pedro Henrique Isaacsson Velho

e17023

Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC) over treatment and time.

David D. Stenehjem

5052

Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.

Andrew J. Armstrong

5029

Genomic characterization of ductal adenocarcinoma of the prostate.

Michael Thomas Schweizer

5030

Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).

Joaquin Mateo

5013

Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.

Gerhardt Attard

5010

Immunotherapy utilizing the combined use of NK and ADCC mediating agents with PARP inhibition.

Kathleen Fenerty

5021

Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.

Abhishek Tripathi

e17027

Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden.

Eric Jay Small

e17010

Investigation of metformin (MET) in patients with castration resistant prostate cancer (CRPC) in combination with enzalutamide (ENZ) vs. ENZ alone: A randomized, open label, phase 2 trial. SAKK 08/14—IMPROVE.

Christian Alexander Rothermundt

TPS5086

KEYNOTE-046: ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC).

Mark N. Stein

5019

KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

Johann S. De Bono

5007

Lean and fat-mass changes following upfront docetaxel compared to androgen deprivation monotherapy in metastatic castration-naïve prostate cancer.

Romy Jose Thekkekara

e17020

Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.

Karim Fizazi

5023

Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.

Shahneen Kaur Sandhu

5040

Microsatellite instability in prostate cancer and response to immune checkpoint blockade.

Wassim Abida

5020

Novel formulation of abiraterone acetate with significantly higher bioavailability and eliminated food effect might allow higher abiraterone exposure and better patient outcome.

Hristos Glavinas

e17036

ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).

Geraldine Martineau

TPS5093

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

Noel Clarke

5003

Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).

Susan Halabi

LBA5005

Overall survival for men with high risk prostate cancer and co-morbidities after treatment with external beam radiotherapy and androgen deprivation therapy.

Nicolette Taku

e17047

Patient and provider variables associated with variation in the systemic treatment of advanced prostate cancer.

Megan Veresh Caram

e17019

Patterns of bone scan and pain response following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).

Lindsey Shantzer

e17011

Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial.

Alan Haruo Bryce

5046

Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.

Julie Nicole Graff

5047

Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy.

Daniel Khalaf

5015

Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP).

Karen A. Autio

5016

Phase I study of HC-1119, an androgen receptor inhibitor: Results from the dose escalation and expansion cohorts.

Feng Bi

e17021

Phase Ib study of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer progressing after one line of chemotherapy and one novel androgen receptor axis inhibitor.

Alejo Rodriguez Vida

TPS5089

Phase II safety and tolerability study of Radium-223 (R223) in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CTRIAL-IE (ICORG) 13-21.

Raymond S. McDermott

5050

Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).

Mark Christopher Markowski

TPS5095

Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.

Ryan Dittamore

5012

Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.

Eric Jay Small

5034

Prevalence of residual tumor in the prostate after contemporary systemic therapy.

Yao Zhu

e17001

Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in men with metastatic, castration-sensitive prostate cancer (mCPSC) undergoing androgen deprivation therapy (ADT) plus docetaxel (D) chemotherapy.

Louis Everest

e17031

Prospective multicenter trial: Hormonal changes by switching from GnRH agonist to GnRH antagonist in patients with early stage of castration resistant prostate cancer as a second line hormonal therapy.

Hiroji Uemura

e17030

Prostate radiotherapy in newly-diagnosed metastatic hormone-sensitive prostate cancer: A single-institution experience.

Scott Carlyle Morgan

5017

PSA density to predict the risk of biochemical relapse in high-risk prostate cancer patients who underwent radical prostatectomy.

Arash Samiei

e17045

Radium-223 re-treatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up.

A. Oliver Sartor

5022

Radium-223 treatment for metastatic prostate cancer: One year data in a single institution experience.

Norma Sidek

e17037

Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).

Chris C. Parker

5024

Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

Charles G. Drake

5027

Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial.

Matthew Raymond Smith

5033

Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.

James L. Gulley

5006

Risk of venous thromboembolism, survival, and expression of procoagulant genes in neuroendocrine versus castration-resistant prostate cancer.

Panagiotis J. Vlachostergios

e17039

Safety data from a phase II randomized trial of radium-223 dichloride (Ra-223) plus enzalutamide (Enza) vs. Enza alone in men with metastatic castration refractory prostate cancer (mCRPC).

Benjamin Louis Maughan

5057

Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.

A. Oliver Sartor

5041

Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.

Kim N. Chi

5028

Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).

Orazio Caffo

5026

Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.

Neeraj Agarwal

TPS5091

Testing the impact of adjuvant radiotherapy (aRT) after radical prostatectomy (RP) on overall mortality (OM) in prostate cancer patients with pathologically node positive disease: A nationwide analysis.

Firas Abdollah

5035

The clinical outcome of second generation anti-hormonal therapy in patients with metastatic castrate-resistant prostate cancer following CHAARTED regimen.

Jaspreet Chahal

e17044

The complete genomic landscape of metastatic prostate cancer pinpoints clinically targetable subgroups.

Lisanne Francisca van Dessel

5014

The poor outcome of patients with mCRPC whom were deemed ineligible for PSMA theranostics based on molecular imaging characteristics.

Sue Ping Thang

e17002

The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity.

Igal Kushnir

e17005

TIPZy (Testosterone Increase Post Zytiga): Increase in serum levels of testosterone (T) after treatment of patients with abiraterone acetate (A) and prednisone (P).

Cy Aaron Stein

e17025

Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression.

Ying Zhang Mazzu

5044

Tumor regression and growth rates of advanced prostate cancer in African American patients treated with docetaxel and prednisone.

Achuta Kumar Guddati

e17049

Unique patterns of the selection and change in circulating tumor cell (CTC) phenotypes and genotypes by drug class in metastatic castration-resistant prostate cancer (mCRPC).

Howard I. Scher

5053

Upfront docetaxel for castration-sensitive metastatic prostate cancer in an ethnically diverse inner-city population.

Surabhi Pathak

e17038